Jaguar Health

About Jaguar Health

Jaguar Health is committed to discovering, developing, and commercializing plant-based prescription medicines to address urgent global health needs. Their mission is encapsulated in their tagline 'Bringing Plant-based Medicines to Life™'. They also focus on sustainability and community benefit sharing while developing first-in-class medicines for unmet medical needs worldwide.

Products & Services

Crofelemer:A plant-based prescription medicine under phase 3 OnTarget trial for preventative treatment of cancer therapy-related diarrhea, and in proof-of-concept studies for rare disease indications like short bowel syndrome and microvillus inclusion disease.

NP-300:A product in the pipeline for gastrointestinal (GI) diseases, at various stages of development.

Canalevia(r)-CA1:A product aimed at gastrointestinal indications, part of the commercial or approved portfolio.

crofelemer

Canalevia

NP-300

Specialties

Plant-based prescription medicines Gastrointestinal (GI) diseases Rare disease indications Sustainability and community benefit sharing cancer therapy-related diarrhea short bowel syndrome microvillus inclusion disease intestinal failure

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 240000 MR: - FA: $240,000 FAN: 240000	D: 2026-01-02 FD: 2026-01-02	1 investors
2	RT: Grant T: - FT: Grant	A: 250000 MR: - FA: $250,000 FAN: 250000	D: 2025-09-25 FD: 2025-09-25	1 investors
3	RT: Bridge Financing T: - FT: Bridge Financing	A: 2570000 MR: - FA: 2.57 million FAN: 2570000	D: 2025-06-24 FD: 2025-06-24	5 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: $1.5 million FAN: 1500000	D: 2025-05-21 FD: 2025-05-21	-
5	RT: Bridge Financing T: - FT: Bridge Financing	A: 3448000 MR: - FA: approximately $3.448 million FAN: 3448000	D: 2025-04-01 FD: 2025-04-01	4 investors
6	RT: Bridge Financing T: - FT: Bridge Financing	A: 3448000 MR: - FA: $3.448 million FAN: 3448000	D: 2025-03-26 FD: 2025-03-26	4 investors

Grant Latest

2026-01-02

$240K

1 investor (Pro only)

Grant 2025-09-25

$250K

Bridge Financing 2025-06-24

$2.6M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lisa Conte

Founder, President, and Chief Executive Officer; Director

M

Massimo Radaelli

President of Jaguar International

P

Pravin Chaturvedi

Chief Scientific Officer and Chair of Scientific Advisory Board

C

Carol Lizak

Chief Financial Officer

S

Steve King

Chief Sustainable Supply, Ethnobotanical Research, and IP Officer

D

David Sesin

Chief Manufacturing Officer

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

Jaguar Health Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised